Arlington Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Core Alternative Capital
CCOR
|
+$8.65M |
| 2 |
AGF US Market Neutral Anti-Beta Fund
BTAL
|
+$4.16M |
| 3 |
Simplify Managed Futures Strategy ETF
CTA
|
+$4.11M |
| 4 |
ProShares Trust Short MSCI EAFE
EFZ
|
+$3.6M |
| 5 |
ProShares Trust Short MSCI Emerging Markets
EUM
|
+$3.54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Innovator Defined Wealth Shield ETF
BALT
|
+$9.98M |
| 2 |
Innovator 20+ Year Treasury Bond 9 Buffer ETF July
TBJL
|
+$513K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 0.62% |
| 2 | Materials | 0.06% |
Similar funds
Arlington Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Arlington Capital Management held 17 positions worth $40.7M, up 269% from $11M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Arlington Capital Management deployed $27.8M of net new capital in Q3 2022, opening 15 new positions. Its largest new stake was Core Alternative Capital: 278,044 shares worth $8.26M.
By sector, the portfolio is most concentrated in Healthcare at 0.62% of assets, up from 0% a quarter earlier, followed by Materials.
On the sell side, the largest reduction was Innovator 20+ Year Treasury Bond 9 Buffer ETF July, an estimated $513K trimmed.
- Arlington Capital Management's largest Q3 2022 buy was Core Alternative Capital: 278,044 shares worth $8.26M.
- Arlington Capital Management's biggest Q3 2022 reduction was Innovator 20+ Year Treasury Bond 9 Buffer ETF July, cutting an estimated $513K.
- Arlington Capital Management fully exited Innovator Defined Wealth Shield ETF in Q3 2022, selling an estimated $9.98M.
- Arlington Capital Management's ten largest holdings make up 96% of its $40.7M portfolio in Q3 2022.
- Arlington Capital Management opened 15 new positions and closed 1 in Q3 2022.
- Arlington Capital Management's portfolio value rose 269% quarter-over-quarter to $40.7M.
Based on Arlington Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.